Benchmark Holdings completes sale of FishVet for £14m

Benchmark Holdings.Benchmark Holdings.
Benchmark Holdings.
Biotech firm Benchmark Holdings, which develops vaccines to keep fish healthy, has completed the sale of its wholly owned subsidiary FVG, known as FishVet, to Pharmaq, part of the global animal health company Zoetis, for a total cash consideration of  £14.4m to £14.7m.

The sale comprises Benchmark's veterinary and diagnostic services activities in the UK, Ireland, Norway and Chile. The final consideration will depend on certain final costs to be borne by Benchmark.

The transaction is another step in Benchmark's strategy to exit non-core areas and focus on its key disciplines in the global aquaculture markets.

Hide Ad
Hide Ad

The sale of FishVet together with the sale of Improve International announced on June 23, raised in aggregate around £27.25m including £3.25m in deferred consideration, in line with expectations.

The sale significantly strengthens the group's financial position and liquidity. To date, the company has sold or exited seven businesses generating up to £30.3m in cash proceeds including £3.75m in deferred consideration.

The Yorkshire company continues to progress the review of its vaccine strategy and the exit from its activities in companion animal products.

Trond Williksen, CEO of Benchmark Holdings, said: "I am very pleased to announce this transaction, the proceeds of which together with those from the sale of Improve International last week, are in line with our expectations.

Hide Ad
Hide Ad

"These disposals represent a significant step forward in our strategy to become a streamlined, profitable business focused on our key areas of competency.

"The FishVet team is a highly talented group. I would like to thank every member of the team and wish them success in the future."

Related topics:

Comment Guidelines

National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.